Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance

2024-9-13

Vorasidenib: a new hope or a false promise for patients with low-grade glioma?

2024-9-12

New clinical trials in CUP and a novel paradigm in cancer classification

2024-9-11

The age of foundation models

2024-9-5

Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach

2024-9-4

Redefining priorities: a call for patient-centred cancer care and research

2024-8-29

Translating biological insights into improved management of endometrial cancer

2024-8-28

Tumour mutational burden: clinical utility, challenges and emerging improvements

2024-8-27

Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer

2024-8-23

The MARIPOSA trials — implications for the treatment of EGFR-mutant NSCLC

2024-8-19

Applications of cell therapy in the treatment of virus-associated cancers

2024-8-19

Blinatumomab improves outcomes in adult MRD-negative BCP-ALL

2024-8-12

Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives

2024-8-2

Anlotinib plus benmelstobart and chemotherapy are effective in ES-SCLC

2024-7-29

Spatial landscapes of cancers: insights and opportunities

2024-7-23

Tisotumab vedotin effective in recurrent cervical cancer

2024-7-22

HER2-targeted therapies beyond breast cancer — an update

2024-7-22

BrECADD raises the bar in classical Hodgkin lymphoma

2024-7-22

BCMA-directed therapy for early relapsed and/or refractory multiple myeloma

2024-7-19

Targeting chromosomal instability in patients with cancer

2024-7-11

Is NETTER-2 a practice-changing trial?

2024-7-9

Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer

2024-7-4

Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins

2024-7-3

Asciminib is safe and effective in patients with newly diagnosed CML

2024-6-25

Vimseltinib improves outcomes in tenosynovial giant cell tumour

2024-6-24

Promising outcomes with liso-cel in patients with R/R follicular lymphoma

2024-6-21

NICHE-2 validates the efficacy of neoadjuvant ICIs in dMMR colon cancer

2024-6-21

Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM

2024-6-18

Osimertinib efficacious as maintenance therapy in patients with stage III NSCLC

2024-6-17

Addition of sintilimab to standard therapy improves event-free survival

2024-6-17

Neoadjuvant ipilimumab–nivolumab superior to adjuvant nivolumab

2024-6-14

Towards equitable AI in oncology

2024-6-7

Exploiting bacteria for cancer immunotherapy

2024-6-5

Bispecific and multispecific antibodies in oncology: opportunities and challenges

2024-5-31

RADICALS-HD sheds light on the role of ADT addition to post-operative radiotherapy

2024-5-30

Ponatinib superior to imatinib in Ph+ ALL

2024-5-28

Adding ibrutinib to frontline therapy improves outcomes in transplant-eligible patients with MCL

2024-5-24

Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain

2024-5-22

Predicting tumour origin with cytology-based deep learning: hype or hope?

2024-5-21

Current understanding and management of CAR T cell-associated toxicities

2024-5-20

Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination

2024-5-17

Cancer mRNA vaccines: clinical advances and future opportunities

2024-5-17

CAR T cells in multiple myeloma: lessons learned

2024-5-7

NIR-II light in clinical oncology: opportunities and challenges

2024-5-1

Adjuvant pembrolizumab improves overall survival in patients with RCC

2024-4-29

Laparoscopic hemihepatectomy is safe and effective

2024-4-29

NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?

2024-4-25

Adjuvant alectinib improves outcomes in ALK-mutant NSCLC

2024-4-25

From AACR 2024

2024-4-25

Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials

2024-4-22